Application of Nanoliposome Alprostadil in the Perioperative Period of Percutaneous Coronary Intervention to Reduce In-Stent Restenosis: A Systematic Review and Meta-Analysis.
Decai ZhuDawei WangZhen ZhaoQingqing LiuRongyuan YangQing LiuPublished in: Journal of interventional cardiology (2023)
In conclusion, the early application of nanoliposome alprostadil after PCI could effectively reduce the occurrence of ISR, and the overall effect of alprostadil treatment in reducing ISR after PCI was relatively stable.
Keyphrases
- percutaneous coronary intervention
- st segment elevation myocardial infarction
- acute coronary syndrome
- st elevation myocardial infarction
- acute myocardial infarction
- coronary artery disease
- antiplatelet therapy
- coronary artery bypass grafting
- atrial fibrillation
- risk assessment
- patients undergoing
- cardiac surgery
- replacement therapy